The Silent Crisis in UAE Chronic Disease: What the Data Tells Us

A growing threat, quietly unfolding

The UAE's modern progress masks a hidden burden: chronic diseases are quietly reshaping public health and straining the economy. Non-communicable diseases account for 55% of all deaths in the UAE, with cardiovascular disease alone responsible for 28%.

Nearly 16.3% of UAE adults have diabetes, rising to 25% among Emirati nationals. This is not a slow burn — it's growing fast, with measurable impacts on patients, providers and payers.

The economic toll is massive

In 2019, NCDs — diabetes, cardiovascular disease and chronic respiratory disease — cost the UAE economy around AED 39.9 billion (≈ US$10.9 billion), accounting for lost productivity and healthcare spending. Primary care services cost approximately AED 4.3 billion that year, over half (52.7%) of which was GP-led, with nearly 20% dedicated to NCD management.

Diabetes care alone cost around AED 372 million, representing 10.7% of primary care expenditure. These figures illustrate a system heavily burdened — and yet underpowered — by chronic care needs.

Treatment costs dissected

Average annual diabetes treatment in the UAE runs about AED 20,700 per patient, climbing higher with complications or age. Dubai-specific spending per diabetic patient is closer to AED 35,500. More than 62% of diabetic patients in Dubai still achieve only poor glycaemic control (HbA1c >7%).

This reveals two urgent problems running in parallel: spiralling cost per patient, and persistent treatment failures in disease control.

The hospitalisation burden

In 2023, Dubai registered 472,713 inpatient admissions — stays that cost the system millions in bed days. Studies show roughly a quarter of COVID-19 hospital admissions in Dubai were driven by diabetes, demonstrating how chronic conditions amplify acute crises.

Hospital dependency remains high, especially among chronic patients. And hospital care is nearly always costlier than well-managed outpatient care.

Clinical performance gaps

A 5-year DHA study of 26,447 diabetic patients revealed only 37.7% achieved HbA1c <7%, with a mean level of 7.76%. Primary-care patients fared slightly better (7.64%) than tertiary-care patients (7.68%) — but both remained clinically insufficient.

This shows that more care isn't automatically better care, emphasising the need for systemic redesign — not just added services.

The GP-led remedy

The data makes one thing clear: continuity matters. A system built on strong GP oversight delivers better outcomes, lower hospital use and tighter cost containment. Redirecting just 15% of unmanaged inpatient cases to proactive GP-led care can quickly pay for itself — through fewer admissions, reduced complications and more efficient utilisation.

But that only works if patients see GPs early. Right now, too many do not.

Misaligned incentives, missed opportunities

When the system pays specialists per visit, hospitals per admission, and insurers per claim, we lose sight of value. What we need is an evidence-based shift toward patient continuity, guided GP referrals and outcome accountability.

Conclusion: data demands action

The facts are clear and non-negotiable. Nearly 40% of people aren't achieving diabetes control. UAE chronic care costs top AED 39 billion annually. Hospital admissions remain high and expensive. GP-led models already show slightly better outcomes.

We can no longer wait. Dubai and Abu Dhabi must move from data recognition to data-driven change.

What 'silent' really means

Diabetes, hypertension and dyslipidaemia rarely announce themselves. They surface as a stroke at 52, a heart attack at 48 or kidney impairment at 60 — outcomes that were preventable a decade earlier if anyone had been tracking the trend. In the UAE roughly 1 in 5 adults has diabetes or prediabetes, and a sizeable share don't know it yet.

What proactive primary care changes

A GP-led model catches these years earlier: an HbA1c at 5.9% triggers a structured lifestyle plan; an LDL of 4.2 triggers a 10-year cardiovascular risk score and a conversation about statin therapy; an office BP of 145/92 triggers home monitoring rather than a single reading dismissed as 'white coat'. The numbers that matter are the ones tracked over years by the same clinician.

Once these conditions reach hospital, the cost — clinical and financial — multiplies. Annual diabetes management at AED 5,900 per patient at the GP level becomes AED 20,000+ once complications start.